Search - tctmd.com

Displaying 21 - 29 of 29

Sort: Relevancy | Date

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

Presentation TCT 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding Focused Commentary

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Martin W Bergmann

October 15, 2015

Presentation TCT 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Brij Maini

October 15, 2015

Presentation TCT 2015

Data Gaps and Future Trial Pathways: Possible Study Designs for New Devices, Anticoagulation Ineligible Patients, and Comparative NOAC Data

Presenter: Nicole Ibrahim, Saibal Kar, Zoltan G. Turi

October 14, 2015

Presentation TCT 2015

Which NOAC for Which Patient?

Presenter: David R. Holmes Jr., Vivek Y. Reddy, Christopher B. Granger

October 11, 2015

Presentation TCT 2014

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Jonathan L. Halperin

September 15, 2014

Presentation TCT 2014

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Presenter: Matthew J. Price, Michael D. Ezekowitz

September 15, 2014

Advertisement

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding Focused Commentary

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding

Data Gaps and Future Trial Pathways: Possible Study Designs for New Devices, Anticoagulation Ineligible Patients, and Comparative NOAC Data

Which NOAC for Which Patient?

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content